HCV Combination Therapies Comprising Pegylated Interferon, Ribavirin and Telaprevir

摘要

The invention relates to combination therapies for the treatment of hepatitis C virus with telaprevir and pegylated interferon alfa-2a with or without ribavirin. The invention relates to the treatment of patients with bridging fibrosis infected with HCV using the combination therapy.